Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report)’s stock price traded up 4.4% on Friday . The stock traded as high as $0.17 and last traded at $0.17. 106,555 shares were traded during trading, a decline of 97% from the average session volume of 4,062,418 shares. The stock had previously closed at $0.16.
Qualigen Therapeutics Stock Up 4.4 %
The stock has a fifty day simple moving average of $0.18 and a 200-day simple moving average of $0.24.
Qualigen Therapeutics (NASDAQ:QLGN – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.
Featured Stories
- Five stocks we like better than Qualigen Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Stock Market Sectors: What Are They and How Many Are There?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Learn Technical Analysis Skills to Master the Stock Market
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.